| Wet Macular Degeneration Trials |
Lucentis
(Ranibizumab, vitreous injection)
AgingEye Times article |
FDA approved. Journal Publications 1
Recruitment completed. call 888-662-6728. Sponsor:Genetech
|
Macugen
(pegaptanib, vitreous injection)
AgingEye Times article |
FDA approved
Journal Publications 1,
2
Recruitment completed.
call 212-824-3100. Sponsor:Eyetech Pharmaceuticals
|
Retaane
(Anecortave, posterior juxtascleral injection
AgingEye Times article |
Phase III completed.
Journal Publications 1,
2
recruitment completed. call 866-692-5959. Sponsor:Alcon
FDA has issued an approvable letter
|
AdPEDF (anti-angiogenic gene therapy)
intravitreal or sub-Tenon injection
AgingEye Times article |
Follow-on Phase I underway.
Press release March 06 RE: Phase I.
Publications 1,
2,
Phase I Results.
Phase I recruitment completed. call 240-632-0740. Sponsor:GenVec
|
EVIZON (anti-angiogenic aminosterol)
(Squalamine, intravenous injection)
AgingEye Times article |
Phase II underway.
Journal Publications 1,
2.
Phase III recruitment begins in 2005. call (800) 299-9156. Sponsor:Genaera
|
Combretastatin A4 Prodrug (CA4P)
Vascular Targeting agent |
Phase I/II underway. call 617-673-7800. Sponsor:OXiGENE, Publications 1
How CA4P works video, Vascular targeting vs. anti-angiogenesis video
|
Cand5
siRNA targeting Vascular Endothelial Growth Factor (VEGF) |
Phase I underway.
currently recruiting patients. call 215-966-6191 .
Sponsor:Acuity Pharmaceuticals, Inc.
|
Sirna-027
siRNA targeting Vascular Endothelial Growth Factor Receptor-1 (VEGFR-1) |
Phase I completed in 2005. Sirna Therapeutics has been acquired by Merck & Co.
In october 2006 (press release). With its strategic partner,
Allergan, Inc., plans are to move Sirna-027 forward into Phase II clinical trials.
Original Developer:Sirna Therapeutics Current Developer: Merck & Co
|
TG100801 Eye drops
Multi-target kinase inhibitor Eye drops |
Phase I completed 02/2007.
Press Release Feb'07
Phase II will start Q3 2007. call 858-678-0760. Sponsor:TargeGen, Inc
|
ATG3 (mecamylamine) Eye drops
Nicotinic acetylcholine (nACh) receptor antagonist |
Phase II underway.
Press Release April'07
Recruiting Patients. call 650-869-7600. Sponsor:CoMentis, Inc. (formerly Athenagen)
|
Envision TD fluocinolone implant
(Retisert) sustained release steroid implant in vitreous
Development suspended by B&L |
In January 2004, Bausch & Lomb decided to focus development of Retisert implant for only posterior uveitis.
Development of Retisert for Macular degeneration is expected to be with later-generation implant technologies or different drugs. Drugs R D 2005;6(2):116-9.
|
Celecoxib with PDT (Celebrex)
Oral anti-inflammatory drug |
Study completed.
recruitment completed. call 800-411-1222. Sponsor:National Eye Institute
|
| Dry Macular Degeneration Trials |
Age-Related Eye Disease Study 2 (AREDS2)
Lutein, zeaxanthin & fish oil supplements in AMD |
Phase III underway.
currently recruiting patients.
Sponsor:National Eye Institute call 1-877-273-3780.
|
OT-551 Antioxidant Eye drops
OT-551 Multicenter Evaluation of Geographic
Atrophy (OMEGA) trial. |
Phase II underway.
Press Release June'07
currently recruiting patients. call (484) 879-2800. Sponsor:Othera Pharmaceuticals
|
Lutein
(Oral carotenoid) |
Study completed.
recruitment completed. call 800-411-1222. Sponsor:National Eye Institute
|
Rheopheresis
(MIRA-1, LEARN-1, LEARN-2)
AgingEye Times article |
Pivotal trial (phase III) underway.
Journal Publications (Full text) 1
currently recruiting patients for LEARN-2. call 877-263-3937. Sponsor:Occulogix
Patient information brochure
|
Genistein
Oral Soy extract |
Phase I underway.
Related journal publications 1,
2
|
| Laser and Surgery Trials |
Submacular Surgery Trials (SST)
surgical removal of subfoveal CNV
AgingEye Times article |
Study has been completed. Final results
1,
2
Submacular surgery is NOT recommended.
Risks outweigh benefits.
|
Transpupillary Thermotherapy for CNV (TTT4CNV)
Infrared laser treatment for occult CNV
AgingEye Times article |
Post Marketing trial completed.
Past publication summary table
Vision-benefit is NOT significant. (primary outcome measure)
Published final results awaited. call 650-940-4700. Sponsor:Iridex
|
Complications of ARMD Prevention Trial (CAPT)
Laser treatment to large drusen to prevent progression to advanced AMD |
Study has been completed. Final results
1
Preventive laser treatment to large drusen does NOT help.
No vision benefit
|
Talaporfin (LS11) PDT
PDT with non-laser LED light |
Phase I underway.
currently recruiting patients. call: 800-695-6941.
Sponsor:Visient Therapeutics (subsidiary of Light Sciences Corporation)
|
Ocular Brachytherapy
Gamma-radiation treatment using a Palladium radioactive button |
Phase I/II underway.
currently recruiting patients. call: 877-960-1234.
Sponsor: Theragenics Corporation
|
| Identification and Treatment of Feeder Vessels indocyanine-green (ICG) angiography guided laser treatment |
Phase I underway.
recruitment completed. call 800-411-1222. Sponsor:National Eye Institute
|
AMD Radiation Therapy Study
(AMDRTS) external beam radiation |
Phase I underway.
Related Publications 1,
2
recruiting patients. call 800-411-1222 or email: sfine@mail.med.upenn.edu
Sponsor:National Eye Institute, Scheie Eye Institute
|
| Limited macular translocation trial |
Phase I underway.
Related journal publications 1,
2
|
CNV Prevention Trial (CNVPT)
laser treatment to fellow eye |
Trial stopped. Early data suggested an increased incidence of CNV in treated eyes. Journal publications
1,
2,
3,
4
|
| Other Macular degeneration Trials |
Implantable Miniature Telescope
IMT™ by Dr. Isaac Lipshitz) |
FDA has found IMT to be "NOT APPROVABLE"
Read Article. Sponsor:VisionCare
|
| Genetic Factors in ARMD
|
currently recruiting patients. call 800-411-1222. Sponsor:National Eye Institute
|
| Preventing Depression in ARMD |
currently recruiting patients. call 215-928-3021.
Sponsor:Thomas Jefferson University Hospital, Philadelphia
|
Medical Dictionary
